^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MULTIVARIATE SUPERVISED LEARNING OF LISOCABTAGENE MARALEUCEL (LISO-CEL) CAR T CELL PRODUCT AND PATIENT CHARACTERISTICS IDENTIFIES ATTRIBUTES ASSOCIATED WITH CLINICAL ENDPOINTS IN LARGE B-CELL LYMPHOMA
Published date:
06/12/2020
Excerpt:
Patient tumor burden and systemic inflammation were associated with liso-cel CAR T cell expansion, efficacy, and safety. The Table summarizes a subset of the attributes associated with expansion, efficacy, and safety of liso-cel CAR T cell therapy.
Trial ID:
